H.C. Wainwright Sticks to Its Buy Rating for CytoDyn (CYDY)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CytoDyn (CYDY) today and set a price target of $1.50. The company’s shares closed last Monday at $1.31.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.6% and a 50.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.
CytoDyn has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.65 and a one-year low of $0.06. Currently, CytoDyn has an average volume of 2.67M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.